{"entity":{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","aka":[],"tldr":"UCSF is the birthplace of oncogene biology (Bishop, Varmus) and KRAS G12C drugging (Shokat), and a leader in I-SPY adaptive breast trials.","summary":"The UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco is the birthplace of oncogene biology, where Bishop and Varmus made their Nobel-winning discovery, and of KRAS G12C drugging through Shokat's switch-II pocket; it holds NCI comprehensive designation and ranks thirty-third in the Newsweek/Statista oncology list. It leads the I-SPY 2 adaptive platform trial in breast cancer under Laura J. Esserman, runs the UCSF500 panel, and pioneered PSMA PET with Thomas A. Hope, alongside neuro-oncology and prostate programmes. OnCo links it to KRAS and PSMA, to gallium-68 PSMA-11, to the Ostrem and Shokat paper, and to the MYC and telomere pathways. Whether MYC can be drugged directly, and tolerated, is the open question it is linked to. Alan Ashworth, Eric J. Small and Alan P. Venook are among the people listed.","asOf":"2026-10-10","wikipedia":"https://en.wikipedia.org/wiki/UCSF_Helen_Diller_Family_Comprehensive_Cancer_Center","links":[{"label":"Official website","url":"https://cancer.ucsf.edu"},{"label":"UCSF breast-cancer studies (includes locally closed studies)","url":"https://clinicaltrials.ucsf.edu/breast-cancer#filter=sex-female-AND-age-18-and-over"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["psma-pet","gamma-knife","radiosurgery-srs"],"targets":["kras","psma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["basket-umbrella-platform"],"trials":["nct06369285","nct07287917","nct06224673","nct04893109","nct04434040","nct05417594","nct06778863","nct06435429","nct06075953","nct05297734","nct06492616","nct05377996","nct06099769","nct06993844","nct03011684","nct06638307","nct05768139","nct05503797","nct07100106","nct07512271","nct05232916","i-spy-2-2","nct05307705","nct05020574","nct07121972","nct04802759","nct05107674","nct05315700","nct06648278","optimice-pcr","nct04606446","nct07145255","nct07487844","nct06982521","nct07413939","ascent-05","nct06841354","nct03990896","nct06533826","wisdom-trial","nct05964504","nct05902507","nct03053193","nct07546331","nct06551116","nct06774027","nct03452774","combomatch","nct06671912","actuate-1801","nct02107703","nct02779751","nct00548236","nct03562637","nct06058377","nct04379570","nct03971409","nct03414658","nct04821141","nct05086692","bwel","nct04862663","capitello-291","nct02498613","nct04266249","tropion-breast02","tropion-breast01","nct04711109","tmist","nct06157892","nct00433511","destiny-breast03","nct04042701","monarche","nct04225117","nct02568267","nct03941730","nct04316117","nct06518057","tailorx","nct05514054","nct05056077","nct06633926","nct01570998","nct07339176","nct06206837","nct01872260","nct04188548","nct03589339","nct03344965","nct05508906","nct05239143","pallas-penelope-b","nct05226871","nct04895358","nct06760637","nct04478279","nct06215469","nct06445738","nct03422003","natalee","nct07218003","nct00070564","nct01674140","nct05840211","nct05323955","nct03157128","nct04457596","nct05548127","nct05573555","patina","pik3ca-2","nct02849496","her2climb-02","nct05563220","nct05593094","nct03737695","nct04395508","nct07659652","nct03906331"],"people":["alan-ashworth","eric-small","rahul-aggarwal","alan-venook","laura-esserman","thomas-hope","emily-bergsland","katherine-matthay","helen-diller","sanford-weill","mitchel-berger","ajai-chari","frank-mccormick","kevan-shokat"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"San Francisco","country":"US","lat":37.765,"lng":-122.458,"institutionType":"cancer-center","website":"https://cancer.ucsf.edu","nci":"comprehensive","newsweekOncology2026":33,"university":"University of California, San Francisco","programs":["I-SPY 2 platform trial","KRAS chemistry","PSMA PET","Neuro-oncology"]},"route":"/institutions/ucsf/","neighbours":{"technology":[{"id":"gamma-knife","kind":"technology","name":"Gamma Knife","route":"/technologies/gamma-knife/"},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"radiosurgery-srs","kind":"technology","name":"Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)","route":"/technologies/radiosurgery-srs/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}],"term":[{"id":"basket-umbrella-platform","kind":"term","name":"Basket, umbrella, and platform trials","route":"/terms/basket-umbrella-platform/"}],"trial":[{"id":"nct05086692","kind":"trial","name":"A Beta-only IL-2 ImmunoTherapY Study","route":"/trials/nct05086692/"},{"id":"nct05593094","kind":"trial","name":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced So","route":"/trials/nct05593094/"},{"id":"nct04478279","kind":"trial","name":"A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors","route":"/trials/nct04478279/"},{"id":"nct06435429","kind":"trial","name":"A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o","route":"/trials/nct06435429/"},{"id":"nct04802759","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","route":"/trials/nct04802759/"},{"id":"nct02107703","kind":"trial","name":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer","route":"/trials/nct02107703/"},{"id":"nct06369285","kind":"trial","name":"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","route":"/trials/nct06369285/"},{"id":"nct06157892","kind":"trial","name":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","route":"/trials/nct06157892/"},{"id":"nct06492616","kind":"trial","name":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","route":"/trials/nct06492616/"},{"id":"nct05377996","kind":"trial","name":"A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors","route":"/trials/nct05377996/"},{"id":"nct06099769","kind":"trial","name":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer","route":"/trials/nct06099769/"},{"id":"nct05514054","kind":"trial","name":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer","route":"/trials/nct05514054/"},{"id":"nct06841354","kind":"trial","name":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","route":"/trials/nct06841354/"},{"id":"nct03157128","kind":"trial","name":"A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET","route":"/trials/nct03157128/"},{"id":"pik3ca-2","kind":"trial","name":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","route":"/trials/pik3ca-2/"},{"id":"nct05503797","kind":"trial","name":"A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations","route":"/trials/nct05503797/"},{"id":"nct04225117","kind":"trial","name":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","route":"/trials/nct04225117/"},{"id":"nct07100106","kind":"trial","name":"A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer","route":"/trials/nct07100106/"},{"id":"nct06206837","kind":"trial","name":"A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.","route":"/trials/nct06206837/"},{"id":"nct02779751","kind":"trial","name":"Abemaciclib with pembrolizumab in breast or lung cancer","route":"/trials/nct02779751/"},{"id":"nct00548236","kind":"trial","name":"Active After Cancer Trial","route":"/trials/nct00548236/"},{"id":"actuate-1801","kind":"trial","name":"Actuate 1801 Part 3B (elraglusib)","route":"/trials/actuate-1801/"},{"id":"nct07512271","kind":"trial","name":"AI patient education for breast oncology","route":"/trials/nct07512271/"},{"id":"nct06215469","kind":"trial","name":"AMMA portable scalp cooling","route":"/trials/nct06215469/"},{"id":"nct06224673","kind":"trial","name":"ARX788 in HER2-low advanced breast cancer","route":"/trials/nct06224673/"},{"id":"ascent-05","kind":"trial","name":"ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)","route":"/trials/ascent-05/"},{"id":"nct04395508","kind":"trial","name":"At-home pertuzumab and trastuzumab expanded access","route":"/trials/nct04395508/"},{"id":"nct04893109","kind":"trial","name":"ATEMPT 2.0","route":"/trials/nct04893109/"},{"id":"nct04434040","kind":"trial","name":"Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)","route":"/trials/nct04434040/"},{"id":"nct03971409","kind":"trial","name":"Avelumab combinations in advanced TNBC","route":"/trials/nct03971409/"},{"id":"nct03414658","kind":"trial","name":"AVIATOR","route":"/trials/nct03414658/"},{"id":"nct02568267","kind":"trial","name":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme","route":"/trials/nct02568267/"},{"id":"nct04821141","kind":"trial","name":"Bazedoxifene plus conjugated estrogens for breast risk biomarkers","route":"/trials/nct04821141/"},{"id":"nct07546331","kind":"trial","name":"Body composition and breast reconstruction outcomes","route":"/trials/nct07546331/"},{"id":"nct06774027","kind":"trial","name":"Breast cancer ADC treatment registry","route":"/trials/nct06774027/"},{"id":"nct05020574","kind":"trial","name":"Breast microbiome and implant infections","route":"/trials/nct05020574/"},{"id":"bwel","kind":"trial","name":"BWEL (Breast Cancer Weight Loss, Alliance A011401)","route":"/trials/bwel/"},{"id":"capitello-291","kind":"trial","name":"CAPItello-291","route":"/trials/capitello-291/"},{"id":"nct04862663","kind":"trial","name":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","route":"/trials/nct04862663/"},{"id":"nct02498613","kind":"trial","name":"Cediranib plus olaparib in advanced solid tumors","route":"/trials/nct02498613/"},{"id":"nct06778863","kind":"trial","name":"CLSP-1025 in p53 R175H solid tumors","route":"/trials/nct06778863/"},{"id":"combomatch","kind":"trial","name":"ComboMATCH (EAY191)","route":"/trials/combomatch/"},{"id":"nct04457596","kind":"trial","name":"CompassHER2 RD","route":"/trials/nct04457596/"},{"id":"nct04266249","kind":"trial","name":"CompassHER2-pCR","route":"/trials/nct04266249/"},{"id":"nct06648278","kind":"trial","name":"COUNTS 2.0 virtual patient navigation","route":"/trials/nct06648278/"},{"id":"nct06075953","kind":"trial","name":"DCIS RECAST","route":"/trials/nct06075953/"},{"id":"nct04711109","kind":"trial","name":"Denosumab for breast cancer prevention in BRCA1 carriers","route":"/trials/nct04711109/"},{"id":"destiny-breast03","kind":"trial","name":"DESTINY-Breast03","route":"/trials/destiny-breast03/"},{"id":"nct06058377","kind":"trial","name":"Durvalumab with chemotherapy in high-risk early breast cancer","route":"/trials/nct06058377/"},{"id":"nct00433511","kind":"trial","name":"E5103 adjuvant chemotherapy with or without bevacizumab","route":"/trials/nct00433511/"},{"id":"nct04188548","kind":"trial","name":"EMBER imlunestrant early study","route":"/trials/nct04188548/"},{"id":"nct03941730","kind":"trial","name":"Estradiol in ER-beta-positive TNBC","route":"/trials/nct03941730/"},{"id":"nct03990896","kind":"trial","name":"Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial","route":"/trials/nct03990896/"},{"id":"nct03422003","kind":"trial","name":"FABREC breast reconstruction radiotherapy","route":"/trials/nct03422003/"},{"id":"nct04316117","kind":"trial","name":"FEATURE FDG-PET/CT response assessment","route":"/trials/nct04316117/"},{"id":"nct05768139","kind":"trial","name":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","route":"/trials/nct05768139/"},{"id":"nct03053193","kind":"trial","name":"FLEX breast cancer gene-expression registry","route":"/trials/nct03053193/"},{"id":"her2climb-02","kind":"trial","name":"HER2CLIMB-02","route":"/trials/her2climb-02/"},{"id":"nct06518057","kind":"trial","name":"Hippocampal-avoidance craniospinal irradiation","route":"/trials/nct06518057/"},{"id":"i-spy-1","kind":"trial","name":"I-SPY 1 (CALGB 150007/150012, ACRIN 6657)","route":"/trials/i-spy-1/"},{"id":"i-spy-2","kind":"trial","name":"I-SPY 2","route":"/trials/i-spy-2/"},{"id":"i-spy-2-2","kind":"trial","name":"I-SPY 2.2","route":"/trials/i-spy-2-2/"},{"id":"nct06633926","kind":"trial","name":"IACS3 integrative cancer survivorship","route":"/trials/nct06633926/"},{"id":"nct01570998","kind":"trial","name":"Intraoperative radiation for breast-conserving surgery","route":"/trials/nct01570998/"},{"id":"nct07339176","kind":"trial","name":"Intratumoral N17350 in Advanced Solid Tumors","route":"/trials/nct07339176/"},{"id":"nct06671912","kind":"trial","name":"LoTam low-dose tamoxifen","route":"/trials/nct06671912/"},{"id":"nct05307705","kind":"trial","name":"LOXO-783 in breast cancer and other solid tumors","route":"/trials/nct05307705/"},{"id":"nct06638307","kind":"trial","name":"MEN2312 in advanced breast cancer","route":"/trials/nct06638307/"},{"id":"nct07121972","kind":"trial","name":"Mirai-MRI breast screening","route":"/trials/nct07121972/"},{"id":"monarche","kind":"trial","name":"monarchE","route":"/trials/monarche/"},{"id":"nct05902507","kind":"trial","name":"MRI simulation for breast radiotherapy","route":"/trials/nct05902507/"},{"id":"natalee","kind":"trial","name":"NATALEE","route":"/trials/natalee/"},{"id":"nct03589339","kind":"trial","name":"NBTXR3 with radiotherapy and anti-PD-1 treatment","route":"/trials/nct03589339/"},{"id":"nct05107674","kind":"trial","name":"NX-1607 in advanced malignancies","route":"/trials/nct05107674/"},{"id":"nct03344965","kind":"trial","name":"Olaparib In Metastatic Breast Cancer","route":"/trials/nct03344965/"},{"id":"nct02849496","kind":"trial","name":"Olaparib with or without atezolizumab in BRCA-mutant breast cancer","route":"/trials/nct02849496/"},{"id":"nct05563220","kind":"trial","name":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer","route":"/trials/nct05563220/"},{"id":"optimice-pcr","kind":"trial","name":"OptimICE-pCR (A012103)","route":"/trials/optimice-pcr/"},{"id":"nct05239143","kind":"trial","name":"P-MUC1C-ALLO1 in advanced solid tumors","route":"/trials/nct05239143/"},{"id":"nct05508906","kind":"trial","name":"Palazestrant combination study","route":"/trials/nct05508906/"},{"id":"pallas-penelope-b","kind":"trial","name":"PALLAS & PENELOPE-B","route":"/trials/pallas-penelope-b/"},{"id":"patina","kind":"trial","name":"PATINA","route":"/trials/patina/"},{"id":"nct07145255","kind":"trial","name":"Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors","route":"/trials/nct07145255/"},{"id":"nct06993844","kind":"trial","name":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors","route":"/trials/nct06993844/"},{"id":"nct06982521","kind":"trial","name":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer","route":"/trials/nct06982521/"},{"id":"nct05232916","kind":"trial","name":"Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects","route":"/trials/nct05232916/"},{"id":"nct05964504","kind":"trial","name":"PLUMB metastatic lobular breast cancer registry","route":"/trials/nct05964504/"},{"id":"nct06445738","kind":"trial","name":"PROSPECTIVE radiotherapy omission","route":"/trials/nct06445738/"},{"id":"psma-prerp","kind":"trial","name":"PSMA-PreRP","route":"/trials/psma-prerp/"},{"id":"nct07487844","kind":"trial","name":"Pulsed electric field ablation in metastatic breast cancer","route":"/trials/nct07487844/"},{"id":"nct07659652","kind":"trial","name":"Quality of life with breast cancer CNS metastases","route":"/trials/nct07659652/"},{"id":"nct06551116","kind":"trial","name":"QuantifyHER","route":"/trials/nct06551116/"},{"id":"nct03737695","kind":"trial","name":"Recurrent or metastatic breast cancer biospecimen registry","route":"/trials/nct03737695/"},{"id":"nct07218003","kind":"trial","name":"RNDO-564 alone or with pembrolizumab","route":"/trials/nct07218003/"},{"id":"nct07413939","kind":"trial","name":"RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive","route":"/trials/nct07413939/"},{"id":"nct03906331","kind":"trial","name":"Selpercatinib RET expanded access","route":"/trials/nct03906331/"},{"id":"nct05226871","kind":"trial","name":"Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies","route":"/trials/nct05226871/"},{"id":"nct03562637","kind":"trial","name":"Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC","route":"/trials/nct03562637/"},{"id":"nct07287917","kind":"trial","name":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors","route":"/trials/nct07287917/"},{"id":"nct05417594","kind":"trial","name":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","route":"/trials/nct05417594/"},{"id":"nct01872260","kind":"trial","name":"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer","route":"/trials/nct01872260/"},{"id":"nct05315700","kind":"trial","name":"Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration","route":"/trials/nct05315700/"},{"id":"nct04895358","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","route":"/trials/nct04895358/"},{"id":"nct06760637","kind":"trial","name":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","route":"/trials/nct06760637/"},{"id":"nct04606446","kind":"trial","name":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","route":"/trials/nct04606446/"},{"id":"nct05840211","kind":"trial","name":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","route":"/trials/nct05840211/"},{"id":"nct05297734","kind":"trial","name":"Supportive cancer care delivery models","route":"/trials/nct05297734/"},{"id":"nct00070564","kind":"trial","name":"SWOG S0221 adjuvant chemotherapy schedules","route":"/trials/nct00070564/"},{"id":"nct01674140","kind":"trial","name":"SWOG S1207 endocrine therapy with or without everolimus","route":"/trials/nct01674140/"},{"id":"nct03452774","kind":"trial","name":"SYNERGY-AI trial matching registry","route":"/trials/nct03452774/"},{"id":"nct05548127","kind":"trial","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)","route":"/trials/nct05548127/"},{"id":"nct05573555","kind":"trial","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)","route":"/trials/nct05573555/"},{"id":"tailorx","kind":"trial","name":"TAILORx","route":"/trials/tailorx/"},{"id":"nct03011684","kind":"trial","name":"Tamoxifen versus letrozole for fertility preservation","route":"/trials/nct03011684/"},{"id":"nct04379570","kind":"trial","name":"Text and telephone support for endocrine therapy","route":"/trials/nct04379570/"},{"id":"tmist","kind":"trial","name":"TMIST (Tomosynthesis Mammographic Imaging Screening Trial)","route":"/trials/tmist/"},{"id":"nct05056077","kind":"trial","name":"Tools To Be Fit","route":"/trials/nct05056077/"},{"id":"nct06533826","kind":"trial","name":"TRADE DXd","route":"/trials/nct06533826/"},{"id":"nct04042701","kind":"trial","name":"Trastuzumab deruxtecan with pembrolizumab","route":"/trials/nct04042701/"},{"id":"tropion-breast01","kind":"trial","name":"TROPION-Breast01","route":"/trials/tropion-breast01/"},{"id":"tropion-breast02","kind":"trial","name":"TROPION-Breast02","route":"/trials/tropion-breast02/"},{"id":"nct05323955","kind":"trial","name":"Tucatinib after isolated brain progression","route":"/trials/nct05323955/"},{"id":"wisdom-trial","kind":"trial","name":"WISDOM (Women Informed to Screen Depending on Measures of Risk)","route":"/trials/wisdom-trial/"}],"person":[{"id":"ajai-chari","kind":"person","name":"Ajai Chari","route":"/people/ajai-chari/"},{"id":"alan-ashworth","kind":"person","name":"Alan Ashworth","route":"/people/alan-ashworth/"},{"id":"alan-venook","kind":"person","name":"Alan P. Venook","route":"/people/alan-venook/"},{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/"},{"id":"eric-small","kind":"person","name":"Eric J. Small","route":"/people/eric-small/"},{"id":"frank-mccormick","kind":"person","name":"Frank McCormick","route":"/people/frank-mccormick/"},{"id":"helen-diller","kind":"person","name":"Helen Diller","route":"/people/helen-diller/"},{"id":"jeffrey-bluestone","kind":"person","name":"Jeffrey A. Bluestone","route":"/people/jeffrey-bluestone/"},{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/"},{"id":"kevan-shokat","kind":"person","name":"Kevan M. Shokat","route":"/people/kevan-shokat/"},{"id":"laura-esserman","kind":"person","name":"Laura J. Esserman","route":"/people/laura-esserman/"},{"id":"mitchel-berger","kind":"person","name":"Mitchel S. Berger","route":"/people/mitchel-berger/"},{"id":"priscilla-chan","kind":"person","name":"Priscilla Chan","route":"/people/priscilla-chan/"},{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/"},{"id":"robin-kate-kelley","kind":"person","name":"Robin Kate Kelley","route":"/people/robin-kate-kelley/"},{"id":"sanford-weill","kind":"person","name":"Sanford I. Weill","route":"/people/sanford-weill/"},{"id":"sean-parker","kind":"person","name":"Sean Parker","route":"/people/sean-parker/"},{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/"}],"drug":[{"id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/"}],"paper":[{"id":"paper-binnewies-tumor-immune-microenvironment-natmed-2018","kind":"paper","name":"Binnewies 2018: understanding the tumour immune microenvironment for effective therapy","route":"/key-papers/paper-binnewies-tumor-immune-microenvironment-natmed-2018/"},{"id":"paper-magbanua-ispy2-ctdna-neoadjuvant-ann-oncol-2021","kind":"paper","name":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","route":"/key-papers/paper-magbanua-ispy2-ctdna-neoadjuvant-ann-oncol-2021/"},{"id":"paper-psma-prerp-hope-jama-oncol-2021","kind":"paper","name":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial","route":"/key-papers/paper-psma-prerp-hope-jama-oncol-2021/"},{"id":"paper-grasso-immune-evasion-colorectal-cancer-discov-2018","kind":"paper","name":"Genetic mechanisms of immune evasion in colorectal cancer","route":"/key-papers/paper-grasso-immune-evasion-colorectal-cancer-discov-2018/"},{"id":"paper-horiuchi-myc-tnbc-cdk-synthetic-lethal-jem-2012","kind":"paper","name":"MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition","route":"/key-papers/paper-horiuchi-myc-tnbc-cdk-synthetic-lethal-jem-2012/"},{"id":"paper-ostrem-kras-g12c-nature-2013","kind":"paper","name":"Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable","route":"/key-papers/paper-ostrem-kras-g12c-nature-2013/"},{"id":"paper-collisson-pancreatic-subtypes-nat-med-2011","kind":"paper","name":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","route":"/key-papers/paper-collisson-pancreatic-subtypes-nat-med-2011/"}],"institution":[{"id":"cz-biohub","kind":"institution","name":"Chan Zuckerberg Biohub","route":"/institutions/cz-biohub/"},{"id":"damon-runyon","kind":"institution","name":"Damon Runyon Cancer Research Foundation","route":"/institutions/damon-runyon/"},{"id":"emerson-collective","kind":"institution","name":"Emerson Collective","route":"/institutions/emerson-collective/"},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"},{"id":"parker-institute","kind":"institution","name":"Parker Institute for Cancer Immunotherapy","route":"/institutions/parker-institute/"}],"pathway":[{"id":"inflammation-nfkb","kind":"pathway","name":"Inflammation & NF-κB","route":"/pathways/inflammation-nfkb/"},{"id":"mrna-translation-eif4f","kind":"pathway","name":"mRNA translation (eIF4F / mTOR)","route":"/pathways/mrna-translation-eif4f/"},{"id":"myc","kind":"pathway","name":"MYC","route":"/pathways/myc/"},{"id":"telomere-maintenance","kind":"pathway","name":"Telomere maintenance & replicative immortality","route":"/pathways/telomere-maintenance/"}],"idea":[{"id":"idea-drugging-myc","kind":"idea","name":"Can MYC be drugged directly, and will patients tolerate it?","route":"/ideas/idea-drugging-myc/"}],"company":[{"id":"quantum-leap-healthcare-collaborative","kind":"company","name":"Quantum Leap Healthcare Collaborative","route":"/companies/quantum-leap-healthcare-collaborative/"}]}}